← 產業報告目錄
Influenza NA Inhibitor Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 120報告編號 APO-67d9f941e7
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Influenza NA Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Influenza NA Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Influenza NA Inhibitor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Influenza NA Inhibitor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Influenza NA Inhibitor include ATK Chemical, Chemwill Asia Co.,Ltd., Green Cross, Moksha8 Pharma, NeoPharm, Shionogi Co., GlaxoSmithKline, Henan DaKen Chemical and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Influenza NA Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Influenza NA Inhibitor Market by Company
ATK Chemical
Chemwill Asia Co.,Ltd.
Green Cross
Moksha8 Pharma
NeoPharm
Shionogi Co.
GlaxoSmithKline
Henan DaKen Chemical
Roche
Influenza NA Inhibitor Segment by Type
Zanamivir
Peramivir
Oseltamivir
Influenza NA Inhibitor Segment by Application
Influenza A Treatment
Influenza B Treatment
Influenza NA Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza NA Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza NA Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza NA Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Influenza NA Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Influenza NA Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Influenza NA Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Influenza NA Inhibitor Market Size (2021-2032)
2.2.2 Global Influenza NA Inhibitor Sales (2021-2032)
2.2.3 Global Influenza NA Inhibitor Market Average Price (2021-2032)
2.3 Influenza NA Inhibitor by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 Zanamivir
2.3.3 Peramivir
2.3.4 Oseltamivir
2.4 Influenza NA Inhibitor by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Influenza A Treatment
2.4.3 Influenza B Treatment
3 Market Competitive Landscape by Manufacturers
3.1 Global Influenza NA Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global Influenza NA Inhibitor Sales (Tons) of Manufacturers (2021-2026)
3.3 Global Influenza NA Inhibitor Revenue of Manufacturers (2021-2026)
3.4 Global Influenza NA Inhibitor Average Price by Manufacturers (2021-2026)
3.5 Global Influenza NA Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of Influenza NA Inhibitor, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Influenza NA Inhibitor, Product Type & Application
3.8 Global Manufacturers of Influenza NA Inhibitor, Established Date
3.9 Global Influenza NA Inhibitor Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 ATK Chemical
4.1.1 ATK Chemical Company Information
4.1.2 ATK Chemical Business Overview
4.1.3 ATK Chemical Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.1.4 ATK Chemical Influenza NA Inhibitor Product Portfolio
4.1.5 ATK Chemical Recent Developments
4.2 Chemwill Asia Co.,Ltd.
4.2.1 Chemwill Asia Co.,Ltd. Company Information
4.2.2 Chemwill Asia Co.,Ltd. Business Overview
4.2.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio
4.2.5 Chemwill Asia Co.,Ltd. Recent Developments
4.3 Green Cross
4.3.1 Green Cross Company Information
4.3.2 Green Cross Business Overview
4.3.3 Green Cross Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.3.4 Green Cross Influenza NA Inhibitor Product Portfolio
4.3.5 Green Cross Recent Developments
4.4 Moksha8 Pharma
4.4.1 Moksha8 Pharma Company Information
4.4.2 Moksha8 Pharma Business Overview
4.4.3 Moksha8 Pharma Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.4.4 Moksha8 Pharma Influenza NA Inhibitor Product Portfolio
4.4.5 Moksha8 Pharma Recent Developments
4.5 NeoPharm
4.5.1 NeoPharm Company Information
4.5.2 NeoPharm Business Overview
4.5.3 NeoPharm Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.5.4 NeoPharm Influenza NA Inhibitor Product Portfolio
4.5.5 NeoPharm Recent Developments
4.6 Shionogi Co.
4.6.1 Shionogi Co. Company Information
4.6.2 Shionogi Co. Business Overview
4.6.3 Shionogi Co. Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.6.4 Shionogi Co. Influenza NA Inhibitor Product Portfolio
4.6.5 Shionogi Co. Recent Developments
4.7 GlaxoSmithKline
4.7.1 GlaxoSmithKline Company Information
4.7.2 GlaxoSmithKline Business Overview
4.7.3 GlaxoSmithKline Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.7.4 GlaxoSmithKline Influenza NA Inhibitor Product Portfolio
4.7.5 GlaxoSmithKline Recent Developments
4.8 Henan DaKen Chemical
4.8.1 Henan DaKen Chemical Company Information
4.8.2 Henan DaKen Chemical Business Overview
4.8.3 Henan DaKen Chemical Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.8.4 Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio
4.8.5 Henan DaKen Chemical Recent Developments
4.9 Roche
4.9.1 Roche Company Information
4.9.2 Roche Business Overview
4.9.3 Roche Influenza NA Inhibitor Sales, Revenue and Gross Margin (2021-2026)
4.9.4 Roche Influenza NA Inhibitor Product Portfolio
4.9.5 Roche Recent Developments
5 Global Influenza NA Inhibitor Market Scenario by Region
5.1 Global Influenza NA Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global Influenza NA Inhibitor Sales by Region: 2021-2032
5.2.1 Global Influenza NA Inhibitor Sales by Region: 2021-2026
5.2.2 Global Influenza NA Inhibitor Sales by Region: 2027-2032
5.3 Global Influenza NA Inhibitor Revenue by Region: 2021-2032
5.3.1 Global Influenza NA Inhibitor Revenue by Region: 2021-2026
5.3.2 Global Influenza NA Inhibitor Revenue by Region: 2027-2032
5.4 North America Influenza NA Inhibitor Market Facts & Figures by Country
5.4.1 North America Influenza NA Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America Influenza NA Inhibitor Sales by Country (2021-2032)
5.4.3 North America Influenza NA Inhibitor Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.5 Europe Influenza NA Inhibitor Market Facts & Figures by Country
5.5.1 Europe Influenza NA Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe Influenza NA Inhibitor Sales by Country (2021-2032)
5.5.3 Europe Influenza NA Inhibitor Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Influenza NA Inhibitor Market Facts & Figures by Country
5.6.1 Asia Pacific Influenza NA Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific Influenza NA Inhibitor Sales by Country (2021-2032)
5.6.3 Asia Pacific Influenza NA Inhibitor Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Influenza NA Inhibitor Market Facts & Figures by Country
5.7.1 South America Influenza NA Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America Influenza NA Inhibitor Sales by Country (2021-2032)
5.7.3 South America Influenza NA Inhibitor Revenue by Country (2021-2032)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Influenza NA Inhibitor Market Facts & Figures by Country
5.8.1 Middle East and Africa Influenza NA Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Influenza NA Inhibitor Sales by Country (2021-2032)
5.8.3 Middle East and Africa Influenza NA Inhibitor Revenue by Country (2021-2032)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Influenza NA Inhibitor Sales by Type (2021-2032)
6.1.1 Global Influenza NA Inhibitor Sales by Type (2021-2032) & (Tons)
6.1.2 Global Influenza NA Inhibitor Sales Market Share by Type (2021-2032)
6.2 Global Influenza NA Inhibitor Revenue by Type (2021-2032)
6.2.1 Global Influenza NA Inhibitor Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global Influenza NA Inhibitor Revenue Market Share by Type (2021-2032)
6.3 Global Influenza NA Inhibitor Price by Type (2021-2032)
7 Segment by Application
7.1 Global Influenza NA Inhibitor Sales by Application (2021-2032)
7.1.1 Global Influenza NA Inhibitor Sales by Application (2021-2032) & (Tons)
7.1.2 Global Influenza NA Inhibitor Sales Market Share by Application (2021-2032)
7.2 Global Influenza NA Inhibitor Revenue by Application (2021-2032)
7.2.1 Global Influenza NA Inhibitor Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global Influenza NA Inhibitor Revenue Market Share by Application (2021-2032)
7.3 Global Influenza NA Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Influenza NA Inhibitor Value Chain Analysis
8.1.1 Influenza NA Inhibitor Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Influenza NA Inhibitor Production Mode & Process
8.2 Influenza NA Inhibitor Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Influenza NA Inhibitor Distributors
8.2.3 Influenza NA Inhibitor Customers
9 Global Influenza NA Inhibitor Analyzing Market Dynamics
9.1 Influenza NA Inhibitor Industry Trends
9.2 Influenza NA Inhibitor Industry Drivers
9.3 Influenza NA Inhibitor Industry Opportunities and Challenges
9.4 Influenza NA Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Influenza NA Inhibitor Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Influenza NA Inhibitor Sales (Tons) of Manufacturers (2021-2026)
Table 7. Global Influenza NA Inhibitor Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Influenza NA Inhibitor Revenue of Manufacturers (2021-2026)
Table 9. Global Influenza NA Inhibitor Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Influenza NA Inhibitor Average Price (US$/Kg) of Manufacturers (2021-2026)
Table 11. Global Influenza NA Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Influenza NA Inhibitor, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Influenza NA Inhibitor, Product Type & Application
Table 14. Global Influenza NA Inhibitor Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Influenza NA Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. ATK Chemical Company Information
Table 19. ATK Chemical Business Overview
Table 20. ATK Chemical Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 21. ATK Chemical Influenza NA Inhibitor Product Portfolio
Table 22. ATK Chemical Recent Developments
Table 23. Chemwill Asia Co.,Ltd. Company Information
Table 24. Chemwill Asia Co.,Ltd. Business Overview
Table 25. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 26. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio
Table 27. Chemwill Asia Co.,Ltd. Recent Developments
Table 28. Green Cross Company Information
Table 29. Green Cross Business Overview
Table 30. Green Cross Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 31. Green Cross Influenza NA Inhibitor Product Portfolio
Table 32. Green Cross Recent Developments
Table 33. Moksha8 Pharma Company Information
Table 34. Moksha8 Pharma Business Overview
Table 35. Moksha8 Pharma Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 36. Moksha8 Pharma Influenza NA Inhibitor Product Portfolio
Table 37. Moksha8 Pharma Recent Developments
Table 38. NeoPharm Company Information
Table 39. NeoPharm Business Overview
Table 40. NeoPharm Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 41. NeoPharm Influenza NA Inhibitor Product Portfolio
Table 42. NeoPharm Recent Developments
Table 43. Shionogi Co. Company Information
Table 44. Shionogi Co. Business Overview
Table 45. Shionogi Co. Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 46. Shionogi Co. Influenza NA Inhibitor Product Portfolio
Table 47. Shionogi Co. Recent Developments
Table 48. GlaxoSmithKline Company Information
Table 49. GlaxoSmithKline Business Overview
Table 50. GlaxoSmithKline Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 51. GlaxoSmithKline Influenza NA Inhibitor Product Portfolio
Table 52. GlaxoSmithKline Recent Developments
Table 53. Henan DaKen Chemical Company Information
Table 54. Henan DaKen Chemical Business Overview
Table 55. Henan DaKen Chemical Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 56. Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio
Table 57. Henan DaKen Chemical Recent Developments
Table 58. Roche Company Information
Table 59. Roche Business Overview
Table 60. Roche Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026)
Table 61. Roche Influenza NA Inhibitor Product Portfolio
Table 62. Roche Recent Developments
Table 63. Global Influenza NA Inhibitor Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 64. Global Influenza NA Inhibitor Sales by Region (2021-2026) & (Tons)
Table 65. Global Influenza NA Inhibitor Sales Market Share by Region (2021-2026)
Table 66. Global Influenza NA Inhibitor Sales by Region (2027-2032) & (Tons)
Table 67. Global Influenza NA Inhibitor Sales Market Share by Region (2027-2032)
Table 68. Global Influenza NA Inhibitor Revenue by Region (2021-2026) & (US$ Million)
Table 69. Global Influenza NA Inhibitor Revenue Market Share by Region (2021-2026)
Table 70. Global Influenza NA Inhibitor Revenue by Region (2027-2032) & (US$ Million)
Table 71. Global Influenza NA Inhibitor Revenue Market Share by Region (2027-2032)
Table 72. North America Influenza NA Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 73. North America Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons)
Table 74. North America Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons)
Table 75. North America Influenza NA Inhibitor Revenue by Country (2021-2026) & (US$ Million)
Table 76. North America Influenza NA Inhibitor Revenue by Country (2027-2032) & (US$ Million)
Table 77. Europe Influenza NA Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 78. Europe Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons)
Table 79. Europe Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons)
Table 80. Europe Influenza NA Inhibitor Revenue by Country (2021-2026) & (US$ Million)
Table 81. Europe Influenza NA Inhibitor Revenue by Country (2027-2032) & (US$ Million)
Table 82. Asia Pacific Influenza NA Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 83. Asia Pacific Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons)
Table 84. Asia Pacific Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons)
Table 85. Asia Pacific Influenza NA Inhibitor Revenue by Country (2021-2026) & (US$ Million)
Table 86. Asia Pacific Influenza NA Inhibitor Revenue by Country (2027-2032) & (US$ Million)
Table 87. South America Influenza NA Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 88. South America Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons)
Table 89. South America Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons)
Table 90. South America Influenza NA Inhibitor Revenue by Country (2021-2026) & (US$ Million)
Table 91. South America Influenza NA Inhibitor Revenue by Country (2027-2032) & (US$ Million)
Table 92. Middle East and Africa Influenza NA Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 93. Middle East and Africa Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons)
Table 94. Middle East and Africa Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons)
Table 95. Middle East and Africa Influenza NA Inhibitor Revenue by Country (2021-2026) & (US$ Million)
Table 96. Middle East and Africa Influenza NA Inhibitor Revenue by Country (2027-2032) & (US$ Million)
Table 97. Global Influenza NA Inhibitor Sales by Type (2021-2026) & (Tons)
Table 98. Global Influenza NA Inhibitor Sales by Type (2027-2032) & (Tons)
Table 99. Global Influenza NA Inhibitor Sales Market Share by Type (2021-2026)
Table 100. Global Influenza NA Inhibitor Sales Market Share by Type (2027-2032)
Table 101. Global Influenza NA Inhibitor Revenue by Type (2021-2026) & (US$ Million)
Table 102. Global Influenza NA Inhibitor Revenue by Type (2027-2032) & (US$ Million)
Table 103. Global Influenza NA Inhibitor Revenue Market Share by Type (2021-2026)
Table 104. Global Influenza NA Inhibitor Revenue Market Share by Type (2027-2032)
Table 105. Global Influenza NA Inhibitor Price by Type (2021-2026) & (US$/Kg)
Table 106. Global Influenza NA Inhibitor Price by Type (2027-2032) & (US$/Kg)
Table 107. Global Influenza NA Inhibitor Sales by Application (2021-2026) & (Tons)
Table 108. Global Influenza NA Inhibitor Sales by Application (2027-2032) & (Tons)
Table 109. Global Influenza NA Inhibitor Sales Market Share by Application (2021-2026)
Table 110. Global Influenza NA Inhibitor Sales Market Share by Application (2027-2032)
Table 111. Global Influenza NA Inhibitor Revenue by Application (2021-2026) & (US$ Million)
Table 112. Global Influenza NA Inhibitor Revenue by Application (2027-2032) & (US$ Million)
Table 113. Global Influenza NA Inhibitor Revenue Market Share by Application (2021-2026)
Table 114. Global Influenza NA Inhibitor Revenue Market Share by Application (2027-2032)
Table 115. Global Influenza NA Inhibitor Price by Application (2021-2026) & (US$/Kg)
Table 116. Global Influenza NA Inhibitor Price by Application (2027-2032) & (US$/Kg)
Table 117. Key Raw Materials
Table 118. Raw Materials Key Suppliers
Table 119. Influenza NA Inhibitor Distributors List
Table 120. Influenza NA Inhibitor Customers List
Table 121. Influenza NA Inhibitor Industry Trends
Table 122. Influenza NA Inhibitor Industry Drivers
Table 123. Influenza NA Inhibitor Industry Restraints
Table 124. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Influenza NA Inhibitor Product Image
Figure 5. Global Influenza NA Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Influenza NA Inhibitor Market Size (2021-2032) & (US$ Million)
Figure 7. Global Influenza NA Inhibitor Sales (2021-2032) & (Tons)
Figure 8. Global Influenza NA Inhibitor Average Price (US$/Kg) & (2021-2032)
Figure 9. Zanamivir Product Image
Figure 10. Peramivir Product Image
Figure 11. Oseltamivir Product Image
Figure 12. Influenza A Treatment Product Image
Figure 13. Influenza B Treatment Product Image
Figure 14. Global Influenza NA Inhibitor Revenue Share by Manufacturers in 2025
Figure 15. Global Manufacturers of Influenza NA Inhibitor, Manufacturing Sites & Headquarters
Figure 16. Global Top 5 and 10 Influenza NA Inhibitor Players Market Share by Revenue in 2025
Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 18. Global Influenza NA Inhibitor Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 19. Global Influenza NA Inhibitor Sales by Region in 2025
Figure 20. Global Influenza NA Inhibitor Revenue by Region in 2025
Figure 21. North America Influenza NA Inhibitor Market Size by Country in 2025
Figure 22. North America Influenza NA Inhibitor Sales Market Share by Country (2021-2032)
Figure 23. North America Influenza NA Inhibitor Revenue Market Share by Country (2021-2032)
Figure 24. United States Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 25. Canada Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 26. Europe Influenza NA Inhibitor Market Size by Country in 2025
Figure 27. Europe Influenza NA Inhibitor Sales Market Share by Country (2021-2032)
Figure 28. Europe Influenza NA Inhibitor Revenue Market Share by Country (2021-2032)
Figure 29. Germany Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. France Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 31. U.K. Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 32. Italy Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. Netherlands Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. Asia Pacific Influenza NA Inhibitor Market Size by Country in 2025
Figure 35. Asia Pacific Influenza NA Inhibitor Sales Market Share by Country (2021-2032)
Figure 36. Asia Pacific Influenza NA Inhibitor Revenue Market Share by Country (2021-2032)
Figure 37. China Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Japan Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. South Korea Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. India Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Australia Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. China Taiwan Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Southeast Asia Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Southeast Asia Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. South America Influenza NA Inhibitor Market Size by Country in 2025
Figure 46. South America Influenza NA Inhibitor Sales Market Share by Country (2021-2032)
Figure 47. South America Influenza NA Inhibitor Revenue Market Share by Country (2021-2032)
Figure 48. Mexico Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Brazil Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Argentina Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Middle East and Africa Influenza NA Inhibitor Market Size by Country in 2025
Figure 52. Middle East and Africa Influenza NA Inhibitor Sales Market Share by Country (2021-2032)
Figure 53. Middle East and Africa Influenza NA Inhibitor Revenue Market Share by Country (2021-2032)
Figure 54. Turkey Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. Saudi Arabia Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. UAE Influenza NA Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Global Influenza NA Inhibitor Sales Market Share by Type (2021-2032)
Figure 58. Global Influenza NA Inhibitor Revenue Market Share by Type (2021-2032)
Figure 59. Global Influenza NA Inhibitor Price (US$/Kg) by Type (2021-2032)
Figure 60. Global Influenza NA Inhibitor Sales Market Share by Application (2021-2032)
Figure 61. Global Influenza NA Inhibitor Revenue Market Share by Application (2021-2032)
Figure 62. Global Influenza NA Inhibitor Price (US$/Kg) by Application (2021-2032)
Figure 63. Influenza NA Inhibitor Value Chain
Figure 64. Influenza NA Inhibitor Production Mode & Process
Figure 65. Direct Comparison with Distribution Share
Figure 66. Distributors Profiles
Figure 67. Influenza NA Inhibitor Industry Opportunities and Challenges
提及公司
ATK ChemicalChemwill Asia Co.,Ltd.Green CrossMoksha8 PharmaNeoPharmShionogi Co.GlaxoSmithKlineHenan DaKen ChemicalRoche
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們